Trials&Research
02 February 2012
The CRO Parexel International is upping its game in Asia, by forming an alliance with the Seoul-based ASAN Medical Center (AMC). The collaboration with the South Korean AMC, the parent of seven hospitals which are part of the Asan Foundation established in 1977, will focus primarily on early phase ...
26 January 2012
Hikma Pharmaceuticals is to partner with the German full-service CRO Ergomed , which will manage clinical trials of Hikma oncology treatments in a pilot project in Jordan. Ergomed will be conducting the first clinical trials for one of Hikma’s key oncology products in Jordanian hospitals, with ...
24 January 2012
Parexel International has established an alliance with University Hospitals Bristol National Health Service (NHS) Foundation Trust (UH Bristol), one of the largest specialist teaching and research hospital trusts in the United Kingdom, to expand its early-phase alliance network. The CRO's alliance ...
12 January 2012
GlaxoSmithKline is set to appeal a ruling by the Supreme Court of Argentine on the fine it was issued regarding the administrative conduct of the COMPAS (Clinical Otitis Media and PneumoniA Study) study in Mendoza. GSK said it "respectfully disagrees" with the decision, which ruled in favour of ...
 
01 February 2012
Last year saw the first in a new class of product for treating hepatitis C infections reach the market. Vertex Pharmaceuticals’ Incivek (telaprevir) and Merck & Co’s Victrelis (boceprevir) are protease inhibitors (to be more accurate, they inhibit viral NS3 serine protease, an enzyme required for ...
26 January 2012
Incoming Thai Prime Minister Yingluck Shinawatra gained much support from the local pharma community last year on announcing a series of health policy goals. She won the mandate to reform the healthcare and other sectors of the Thai economy after her PTP party’s landslide victory in the July 2011 ...
24 November 2011
The Russian law on circulation of medicines, which came into effect in September 2010, brought some clarification to the clinical trial approvals framework, but also a great deal of uncertainty and confusion. One year on, the situation has stabilised in a number of respects, but some grey areas ...
22 November 2011
Why? With so many maybes in clinical trials, from patient recruitment numbers to site start -up times, there are enough uncertainties that could hamper clinical study success; risk management is one factor that you can bank on. Fiona Racher and Dr John Bennett show how to formulate a system that ...
 
Exco InTouch hires CTO Exco InTouch , a provider of mobile patient engagement and communication solutions has hired Madhav Vattikuti as Chief Technology Officer (CTO). Vattikuti’s role will see him use his significant technology expertise and background to strengthen delivery and development of Exco InTouch’s market ... Chiltern adds therapeutic experts to team The CRO Chiltern International has hired Drs Marcelo Piccirillo and Carlo Lanza to its medical teams. Dr Piccirillo will serve as senior clinical research physician with special emphasis in developing the gastroenterology therapeutic area. He has 20 years experience in the medical and clinical ... Henauer joins i3 as head of resourcing PharmaNet/i3 , inVentiv Health’s clinical segment, has hired Dr Stephan Henauer as executive director, i3 Pharma Resourcing. In this role, Dr Henauer will provide leadership for PharmaNet/i3’s staffing business in central, eastern and northern Europe. Prior to joining PharmaNet/i3, Dr Henauer was ...
 
Deals such as ICON’s recent acquisition of BeijingWits Medical Consulting not only reflect the opportunity presented by emerging growth markets but also the need for local knowledge to conduct business effectively and tailor new product development to local market needs. We expect more deals to ...
Every medicine has associated side effects, or adverse drug reactions (ADRs). The European Impact Assessment Report on Pharmacovigilance (PV) estimated that approximately 5% of all hospital admissions are due to ADRs and that ADRs are the fifth most common cause of hospital death, accounting for an ...
Lifestyle, living standards and longevity will all play their part in the disease profile of the future global population. Aligned with these factors is the shifting market for pharmaceuticals, an increasing proportion of profits will come from outside of the US and Europe as the developing world ...
In Europe, there is a common set of rules that regulate the collection, use, and sharing of personal data. These include strict protection of sensitive data such as health data. However, individual European countries have interpreted and implemented the rules on the use of health data in clinical ...
Lean methods for transformation, believes Deloitte 's Julian Remnant , could form a foundation for multi-company collaborations that might define the next generation of industry partnerships. In my April column, I recognised the benefits R&D organisations have realised from the first generation of ...
Information technology investments in R&D will begin to target the ‘value analytics’ agenda, believes Deloitte 's Julian Remnant , and to do so, he suggests sponsors will increasingly draw on their delivery partners to shape operational IT strategy. The last ten years has seen industry-wide IT ...
 

EVENTS
04 March 2012
The Marriott World Center, Orlando, Florida
 
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36